Aristeia Capital’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Aristeia Capital’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-1,500,000	Closed	-$1.03M	–	599
2020 Q4	$1.03M	Sell	1,500,000 -6,100,000	-80%	-$13M	0.03%	246
2020 Q3	$17.1M	Buy	7,600,000 +3,843,728	+102%	+$11M	0.7%	30
2020 Q2	$13.4M	Sell	3,756,272 -1,468,728	-28%	-$5.3M	0.69%	22
2020 Q1	$19.9M	Sell	5,225,000 -366,743	-7%	-$1.21M	1.68%	13
2019 Q4	$16.8M	Buy	+5,591,743	New	+$14.5M	1.11%	19

Other funds holding BMY.RT

JCI

Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return

Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return

TNB

Thomasville National Bank Thomasville, Georgia $1.82B AUM

WAM

Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return

IAIM

International Assets Investment Management Orlando, Florida $1.44B AUM 21.92% 1-Year Est. Return

Aristeia Capital's BMY.RT Position: Q1 2021 in Review

Aristeia Capital sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 1,500,000 shares — an estimated $1.03M sold.

Aristeia Capital first reported a position in BMY.RT in Q4 2019 and held it in 5 quarters. The position peaked at $19.9M in Q1 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

Aristeia Capital reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
Aristeia Capital sold 1,500,000 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $1.03M.
Aristeia Capital first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 5 quarters.
Aristeia Capital's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $19.9M in Q1 2020.
12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Aristeia Capital's 13F filing for Q1 2021, filed 17 May 2021.